Abstract

According to a Prognoscan database, upregulation of Bruton's tyrosine kinase (Btk) is associated with low overall survival in ovarian cancer patients. We found that spheroids-forming ovarian cancer cell, which highly expressed cancer stem-like cell (CSC) markers and Btk, were cisplatin resistant. We next treated CSCs and non- CSCs by a combination of ibrutinib and cisplatin. We found that chemoresistance was dependent on Btk and JAK2/STAT3, which maintained CSC by inducing Sox-2 and prosurvival genes. We suggest that addition of ibrutinib to cisplatin may improve treatment outcome in ovarian cancer.

Original languageEnglish
Pages (from-to)13255-13268
Number of pages14
JournalOncotarget
Volume6
Issue number15
Publication statusPublished - 2015

Keywords

  • Bruton's tyrosine kinase (Btk)
  • Cancer stem cell (CSC)
  • Cisplatin
  • Ibrutinib
  • Ovarian cancer
  • Spheroids

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Bruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer'. Together they form a unique fingerprint.

  • Cite this